MYGN Aug 2024 10.000 put
- Zacks
QIAGEN (QGEN) Develops Test for Research and CDx Application
QIAGEN's (QGEN) next-generation sequencing test aims to aid personalized medicine research in solid tumor types, including ovarian cancer, and improve decentralized testing capabilities.
- GlobeNewswire
QIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global research and companion diagnostics applications
Next-generation-sequencing-based homologous recombination deficiency (HRD) assay based on QIAGEN’s QIAseq xHYB technology, QIAGEN Digital Insight solutions, and Myriad’s proprietary, FDA-approved MyChoice CDx® biomarkers QIAGEN to make kit-based HRD test available globally to support research and companion diagnostics development in collaboration with pharmaceutical partners enabling wider adoption and potential clinical indication expansion for MyChoice CDx Project builds on recently announced
- GlobeNewswire
Myriad Genetics Showcases New Research and Product Innovations Advancing Cancer Care at 2024 ASCO® Annual Meeting
Molecular Residual Disease (MRD) study and multiple RiskScore studies among seven new datasets to be shared by Myriad and CollaboratorsSALT LAKE CITY, May 23, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, and its collaborators will share data from seven studies at the 2024 ASCO Annual Meeting. Three studies led by Myriad focus on breast cancer risk assessment, and four additional studies will be shared by collaborators that wi
